Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Biosynthesis of PGD2 in Vivo (Niacin)

This study has been completed.
Sponsor:
Collaborator:
American Heart Association
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01275300
First received: December 16, 2010
Last updated: May 14, 2013
Last verified: March 2012

December 16, 2010
May 14, 2013
July 2007
January 2012   (final data collection date for primary outcome measure)
Area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin and aspirin [ Time Frame: -2-0, 0-2, 2-4, 4-6, 6-12 and 12-24 hours pre or post niacin ] [ Designated as safety issue: No ]
Area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied. Area under the urinary prostaglandins concentration versus time curve (AUC) in response to aspirin will also be studied.
Same as current
Complete list of historical versions of study NCT01275300 on ClinicalTrials.gov Archive Site
Area under the flushing response versus time curve (AUC) in response to niacin [ Time Frame: 5 mins before niacin to 6 hours after niacin administertion (continuously) ] [ Designated as safety issue: No ]
Area under the flushing response versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied.
Area under the flushing response versus time curve (AUC) in response to niacin [ Time Frame: 5 mins before niacin to 6 hours after niacin administertion (continuesly) ] [ Designated as safety issue: No ]
Area under the flushing response versus time curve (AUC) in response to niacin with or without pretreatment of aspirin will be studied.
Not Provided
Not Provided
 
Biosynthesis of PGD2 in Vivo
A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin

We would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin.

Phase I: 5 days of 81 mg aspirin/placebo followed by 600 mg Niacin, 2 week washout and 5 days taking the alternate. The order in which this is given will be randomized or assigned by chance.

Phase II: One study week consisting of 5 days of taking 81 mg Aspirin, taken once daily, followed by a single dose of 600 mg Niacin on day 6.

Phase III: 5 days taking 81 mg Aspirin/placebo, 10 day washout in between.

Phase IV: Use of extended release niacin instead of instant release.

Phase V: A Celebrex study is necessary to explore the contribution of Cox-2 to niacin induced flushing.

The purpose of this study is to look at the roles of various blood cells and their contributions of different prostaglandins. The intention is that by better understanding these prostaglandins and various metabolites, it will provide insights into their roles in the cardiovascular system.

Prostaglandins and metabolites are naturally occurring substances found in the blood and urine which can act as markers which can be quantified and studied as we will be doing in this study. Flushing response to niacin will also be assessed by laser doppler measuring blood flow of the facial skin.

Untransformed and transformed data will be subjected to exploratory analysis of variance appropriated for a three factor design with one two period crossover factor and two non-repeated factors. Additionally, volunteer's test(s) for paired observations will characterize the magnitude of the niacin effect on the response variables within selected time points.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Healthy Volunteer
  • Dietary Supplement: 5 days of placebo followed by 600mg niacin
    600 mg niacin
    Other Name: Niaspan
  • Dietary Supplement: aspirin first
    5 days taking 81 mg Aspirin followed by a single dose of 600 mg Niacin
    Other Names:
    • baby aspirin
    • niaspan
  • Drug: 81 mg Aspirin
    5 days taking 81 mg Aspirin
    Other Names:
    • low dose aspirin
    • baby aspirin
  • Dietary Supplement: Niaspan
    dosage
    Other Name: niacin
  • Drug: Celebrex and niacin
    Data will be handled exactly like phase 1.
    Other Name: niacin
  • Placebo Comparator: Phase I, Period B
    Period B: 5 days of placebo, followed by a single dose of 600mg niacin.
    Intervention: Dietary Supplement: 5 days of placebo followed by 600mg niacin
  • Placebo Comparator: sugar pill
    Intervention: Dietary Supplement: aspirin first
  • Placebo Comparator: low dose aspirin or placebo
    5 days taking either 81 mg aspirin/placebo with at least 10 day washout in between.
    Intervention: Drug: 81 mg Aspirin
  • Active Comparator: Single dose 2 gms Niaspan for 8 days
    Intervention: Dietary Supplement: Niaspan
  • Placebo Comparator: Celebrex / Placebo
    Celebrex 200 mg/Placebo taken for 5 days, two times daily, followed by single dose of 600 mg niacin on day five. At least 10 days in between each dosing period.
    Intervention: Drug: Celebrex and niacin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
January 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

age between 18-70

  • subject must be in good health as based on medical history
  • All subjects must be non-smoking, non-pregnant volunteers
  • Female subjects of child bearing potential must be using a medically acceptable method of contraception throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and just prior to the start of each treatment period of the study, which must be negative at all time points.

Exclusion Criteria:

  • subjects with any medical condition that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.
  • subjects who have received an experimental drug within 30 days prior to the study.
  • subjects who have taken medications at least 10 days prior to the study. Birth Control pills are acceptable and shall not be excluded.
  • Subjects who have taken aspirin or aspirin containing products for at least 10 days prior to the study.
  • Subjects who have taken acetaminophen, NSAIDS, COX-2 inhibitors (OTC or prescription) for at least 10 days prior to the study.
  • Subjects who are currently consuming any type of tobacco product(s).
  • Subjects who consume high doses of antioxidant vitamins daily (vitamin C > 1000mg, Vitamin E > 400 IU, Beta Carotene > 1000IU, Vitamin A > 5000IU, Selenium > 200mcg, Folic Acid > 1mg) for the 2 weeks prior to the start of the study and throughout the study.
  • Subjects who consume alcohol, caffeine or high fat food 24 hours prior to study.
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01275300
806115 - FitzGerald, MD, American Heart Association
Yes
University of Pennsylvania
University of Pennsylvania
American Heart Association
Not Provided
University of Pennsylvania
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP